Introduction
============

Hepatocellular carcinoma is the fifth most frequent type of cancer in the global prevalence, and the third leading cause of cancer death. The Chinese prevalence of hepatocellular carcinoma accounts for 55% of the global prevalence, and carcinoma ranks second amongst cancer mortality rates in China ([@b1-ol-0-0-7174]). Approximately 30--40% of patients with hepatocellular carcinoma get an early diagnosis with indications for surgical resection ([@b2-ol-0-0-7174]). The 5-year survival of advanced hepatocellular carcinoma is only 30--45% ([@b3-ol-0-0-7174]).

Sorafenib is an oral multi-kinase inhibitor for multiple signaling pathways. It can block the proliferation of tumor cells, inhibit angiogenesis and induce cell apoptosis, and has therefore been used against cancerous tissues ([@b4-ol-0-0-7174]). Several clinical studies have confirmed that sorafenib alone or in combination with other chemotherapies can prolong the survival in advanced hepatocellular carcinomas ([@b5-ol-0-0-7174],[@b6-ol-0-0-7174]).

Small hepatocellular carcinoma refers to a single lesion \<5 cm in diameter, or up to three lesions \<3 cm in diameter. Several studies have confirmed that radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), microwave ablation, transcatheter arterial chemoembolization (TACE) and high intensity focused ultrasound (HIFU) have good safety and efficacy profiles in the treatment of early hepatocellular carcinoma ([@b7-ol-0-0-7174],[@b8-ol-0-0-7174]). These are important alternatives for whenever there are surgical contraindications due to an unsatisfactory tumor location, intolerance of surgical risk due to underlying conditions, or refusal of surgical treatment ([@b9-ol-0-0-7174]). This study further analyses the efficacy and short-term outcome of a therapy with sorafenib combined with RFA against early small hepatocellular carcinoma.

Subjects and methods
====================

### Subject information

The patients who were diagnosed for the first time, and pathologically confirmed as presenting a primary small hepatocellular carcinoma, were successively enrolled in this study. Patients excluded from the study had active viral hepatitis, severe cirrhosis, other liver diseases (such as fatty liver, alcoholic liver disease, autoimmune liver diseases); they could not complete required course of RFA and sorafenib therapy; or there was incomplete clinical information available for them. The Ethics Committee of Zhumadian Central Hospital approved the study and patients or their families signed written informed consents. A total of 50 cases of single RFA therapy (control group) and 40 cases of RFA combined with oral sorafenib (treatment group) participated. [Table I](#tI-ol-0-0-7174){ref-type="table"} lists the baseline information of the patients.

### Methods

This study was performed by a single surgery and nursing team, which followed standard medical procedures. For RFA, the patient was in dorsal position under general anesthesia. The percutaneous puncture was guided by ultrasound (Aloka SSD-1100 Color Doppler Ultrasound; Siemens AG, Munich, Germany), Cool-tip RF system (Valleylab, Boulder, CO, USA), output frequency was 460 kHz, and maximum power 150 W. Seven to twelve fine electrode needles were in the tip of a 14 G trocar, a spherical thermocoagulation focus (5.0 cm) was formed after electrification. The actual power of RFA was 90 W, the temperature was set at 100°C, the ablation was terminated after achieving the preset temperature for 15 min. After that, the ultrasound was used again to scan the ablation region. By modifying the location of the electrode needle, re-ablation could be performed based on the size of the tumor. The goal was to obtain high-echogenicity throughout the ablation region, which was 0.5--1 cm larger than the initial tumor lesion. After treatment, the unfolded electrode was taken out; the needle was withdrawn. The power of radio frequency was increased by 60 W in a stepwise manner to intensify the resistance. The treatment was done once the evaporation region of high echo covered the boundary of the tumor site. The needle was burnt after each withdrawal to prevent bleeding and metastasis. Contrast-enhanced abdominal CT was performed 1, 3, 6 and 12 months after treatment and then every 6 months after that. Re-ablation of new lesions was possible.

The patients in the combination therapy group were administrated sorafenib (registry no. H20130137; Bayer Pharma AG, Berlin, Germany) orally 400 mg, bid, for 4 weeks.

### Observational measurements and detection methods

The median follow-up period was 35 months (6--50 months). Tumor-free survival, relapse and survival rates, RFA interval and number of treatments, overall efficacy and incidence of complications were all parameters evaluated. Additionally, serum levels of vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), hypoxia inducible factor-1α (HIF-1α) and osteopontin (OPN) were measured. The efficacy of the treatment was evaluated according to the Response Evaluation Criteria In Solid Tumors (RESIST) scale, using the following formula: Overall efficacy = (CR+PR+SD)/overall number × 100%, where CR is complete response, PR is partial response, SD is stable disease and PD is progressive disease. Peripheral venous blood (6 ml) was collected. The samples were left to settle for 30 min, before centrifugation at 3,000 × g for 20 min. The supernatants were then isolated and stored at −20°C for subsequent testing. The enzyme levels in the serum samples were determined using enzyme-linked immunosorbent assay (ELISA) tests according to the instructions in the kits used. All ELISA reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), and the microplate reader was purchased from Bio-Rad Laboratories, Inc. (Hercules, CA, USA).

### Statistical analysis

SPSS 20.0 software (IBM, Armonk, NY, USA) was used for statistical analysis. Measurement data are presented by mean ± standard deviation, inter-group differences were analyzed by independent sample t-tests, and intra-group differences by paired t-tests. Categorical data were analyzed by number or percentage (%), and inter-group differences were analyzed by Chi-square tests. The survival rate was calculated using at Kaplan-Meier model and the log-rank Chi-square test. A P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Tumor-free survival, relapse and overall survival rates

The patients in treatment group had more prolonged tumor-free survival, lower relapse and longer survival rates; these differences compared to the patients in the control group were all significant (P\<0.05) ([Table II](#tII-ol-0-0-7174){ref-type="table"}).

### RFA interval and number of treatments

Compared to the control group, the patients in the treatment group had a significantly longer average interval of RFA and a decreased number of treatments (P\<0.05) ([Table III](#tIII-ol-0-0-7174){ref-type="table"}).

### Overall efficacy and the incidence of complications

Also, when compared to the patients in the control group, those in the treatment group had a superior overall treatment efficacy; however, no differences were found between the groups in the incidence of complications ([Table IV](#tIV-ol-0-0-7174){ref-type="table"}).

### Serum levels of VEGF, CTGF, HIF-1α and OPN

No significant differences were found between the average levels of serum VEGF, CTGF, HIF-1α and OPN between treatment and control groups before treatment, P\>0.05. After treatment, however, all the levels in both treatment group and control group were lower, but significantly more so in the treatment group, P\<0.05.

Discussion
==========

RFA can achieve complete necrosis of tumor tissues in a target region, with only limited injury of surrounding tissues. As a result, RFA has been extensively applied in early and moderately advanced hepatocellular carcinoma. Advantages such as the small wound it leaves, its convenience and applicability, the small probability of complications, and the requirement for only a short hospitalization period make this method a common one ([@b10-ol-0-0-7174]). Relapse after treatment is the major factor affecting long-term survival ([@b11-ol-0-0-7174]). RFA focuses on imaging-visible lesions, thus residual tiny lesions or satellite lesions may cause relapse ([@b12-ol-0-0-7174]). In addition, there are other factors that may affect the efficacy of RFA, such as the shape and distribution of the tumor, the ablation range and radiofrequency conditions ([@b13-ol-0-0-7174]).

Sorafenib is a targeting drug; it can inhibit tumor growth through inhibiting the activation of MAPK, JAK and Wnt signaling pathways ([@b14-ol-0-0-7174]). Sorafenib can also inhibit the activity of tyrosine receptors, which are closely associated with tumor growth and progress, including VEGF receptor 2, VEGF receptor 3, platelet-derived growth factor receptor 2 and c2KIT proto-oncogene. Sorafenib has been shown to block neovascularization in tumors and inhibit tumor growth indirectly ([@b15-ol-0-0-7174]). Moreover, sorafenib can induce tumor cell apoptosis or necrosis and increased autophagy ([@b16-ol-0-0-7174]). Currently, the efficacy of sorafenib for the treatment of advanced hepatocellular carcinoma, renal, colorectal, breast and cervical cancers is satisfactory ([@b17-ol-0-0-7174]).

Whether active chemotherapy should be used after surgery for early small hepatocellular carcinoma is still a controversial question, but most investigators support the notion that chemotherapy can further decrease the tumor relapse rate ([@b18-ol-0-0-7174]). This study used sorafenib in combination with RFA to treat early small hepatocellular carcinoma, with results that argue for the superiority of this approach. In the observation group, the tumor-free survival was prolonged (12.3 months), the relapse rate decreased (15.0%), the survival rate increased (87.5%), the mean interval of RFA prolonged, and the number of required treatments decreased, the overall efficacy increased (82.5%), and the incidence of complications (17.5%) was similar to that in the control group. Our results indicate that sorafenib in combination with RFA is safe and efficacious in the treatment of early small hepatocellular carcinoma. In comparison with a previous study of surgery alone, the survival rate was increased and the relapse rate was decreased ([@b19-ol-0-0-7174]). Importantly, after treatment, the serum levels of known pro-tumorigenic factors VEGF, CTGF, HIF-1α and OPN in treatment group were significantly lower than those in the control group, P\<0.05. VEGF is an angiogenic factor in many malignancies, and the level of VEGF is closely related to the staging of TNM, clinical efficacy, survival and the prognosis ([@b20-ol-0-0-7174]). CTGF secreted by tumor cells can promote the synthesis of DNA and proliferation of tumor cells ([@b21-ol-0-0-7174]). HIF-1α is involved in the metabolism, growth and metastasis of tumor cells, can increase the blood supply and oxygen utilization coefficient, and further improve the adaptability of tumor cells to hypoxic microenvironments ([@b22-ol-0-0-7174]). OPN is a bio-marker of hypoxia in tumor tissue, it can promote apoptosis and necrosis of tumor cells ([@b23-ol-0-0-7174]).

In conclusion, sorafenib in combination with percutaneous RFA is safe and effective in the treatment of early small hepatocellular carcinoma; this treatment can decrease serum levels of active tumor growth factors VEGF, CTGF, HIF-1α and OPN, and is thus worthy of consideration. That said, the small sample size of our study and short follow-up period, call for larger studies for further validation.

###### 

Baseline information.

  Group                         Control group (n=50)   Treatment group (n=40)   t/χ^2^   P-value
  ----------------------------- ---------------------- ------------------------ -------- ---------
  Male/female                   28/22                  23/17                    0.020    0.887
  Age (years)                   53.6±12.4              55.7±13.6                0.127    0.763
  Maximum tumor diameter (cm)   2.5±1.2                2.6±1.4                  0.223    0.635
  No. of tumors                 1.5±0.5                1.4±0.3                  0.152    0.732
  AFP (µg/l)                    562.4±56.7             594.7±62.3               0.327    0.649
  ALT (U/l)                     65.7±12.3              64.8±13.5                0.217    0.658
  Overall bilirubin (µmol/l)    19.2±4.3               21.3±4.5                 0.232    0.612
  Albumin (g/l)                 42.5±3.6               41.7±3.8                 0.128    0.745

AFP, alpha-fetoprotein; ALT, alanine aminotransferase.

###### 

Tumor-free survival, relapse and survival rate.

  Groups      N    Tumor-free survival (months)   Relapse rate, n (%)   Survival rate, n (%)
  ----------- ---- ------------------------------ --------------------- ----------------------
  Control     50   8.4                            17 (34.0)             35 (70.0)
  Treatment   40   12.3                           6 (15.0)              35 (87.5)
  χ^2^             8.324                          4.217                 3.938
  P-value          0.006                          0.040                 0.047

###### 

RFA interval and number of treatments.

  Groups      Mean interval (months)   No. of treatments
  ----------- ------------------------ -------------------
  Control     3.6±0.8                  2.3±0.6
  Treatment   5.5±1.3                  1.9±0.5
  t-test      5.624                    5.237
  P-value     0.027                    0.032

RFA, radiofrequency ablation.

###### 

Overall efficacy and incidence of complications, n (%).

  Groups      n    CR   PR   SD   PD   Overall efficacy   Infection   Bleeding   Ascites   Injury of bile duct   Liver dysfunction   Diarrhea or constipation   Hand-foot reaction or dental ulcer   Total incidence
  ----------- ---- ---- ---- ---- ---- ------------------ ----------- ---------- --------- --------------------- ------------------- -------------------------- ------------------------------------ -----------------
  Control     50   5    16   10   19   31 (62.0)          2           2          2         2                     1                   1                          0                                    10 (20.0)
  Treatment   40   10   16   7    7    33 (82.5)          0           1          1         1                     0                   2                          2                                    7 (17.5)
  χ^2^                                 4.546                                                                                                                                                         0.091
  P-value                              0.033                                                                                                                                                         0.763

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

###### 

Serum levels of VEGF, CTGF, HIF-1α and OPN.

              VEGF (pg/ml)   CTGF (pg/ml)   HIF-1α (pg/ml)   OPN (µg/l)                                          
  ----------- -------------- -------------- ---------------- ------------ ------------ ------------ ------------ ------------
  Control     567.4±65.7     256.7±34.5     765.8±86.5       465.9±55.3   254.3±56.4   156.2±23.7   153.2±23.6   67.8±21.3
  Treatment   584.9±58.3     426.3±46.7     774.2±92.3       623.5±76.4   276.5±58.9   224.3±45.6   167.4±32.4   132.4±24.5
  t-test      0.125          6.527          0.163            6.238        0.213        5.968        0.185        5.754
  P-value     0.862          0.012          0.824            0.016        0.742        0.020        0.768        0.023

VEGF, vascular endothelial growth factor; CTGF, connective tissue growth factor; HIF-1α, hypoxia inducible factor-1α; OPN, osteopontin.
